The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand therapies, the increasing number of radioligand therapies that are under clinical trials, and the increasing interest of major pharmaceutical companies toward it..

放射性配体疗法的市场预计将在未来几年显着增长。这是由于被诊断患有癌症的患者数量不断增加，对放射性配体疗法的认识不断提高，正在进行临床试验的放射性配体疗法数量不断增加，以及主要制药公司对它的兴趣越来越大。。

LAS VEGAS, July 9, 2024 /PRNewswire/ -- DelveInsight's Radioligand Therapies Market Insights report includes a comprehensive understanding of current treatment practices, emerging radioligand therapies, market share of individual therapies, and current and forecasted Radioligand Therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

拉斯维加斯，2024年7月9日/PRNewswire/--DelveInsight的放射性配体疗法市场见解报告包括对当前治疗实践，新兴放射性配体疗法，个体疗法的市场份额以及2020年至2034年当前和预测的放射性配体疗法市场规模的全面了解，细分为700万[美国，欧盟4国（意大利，西班牙，法国和德国），英国和日本]。。

Key Takeaways from the Radioligand Therapies Market Report

放射性配体疗法市场报告的主要收获

As per DelveInsight's analysis, the radioligand therapies market is anticipated to grow at a significant CAGR by 2034.

根据DelveInsight的分析，到2034年，放射性配体疗法市场预计将以显着的复合年增长率增长。

Leading radioligand therapy companies such as Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca, Endocyte, Progenics Pharmaceuticals, Inc., AdvanCell Isotopes Pty Limited, and others are developing novel radioligand therapies that can be available in the radioligand therapies market in the coming years..

领先的放射性配体治疗公司，如Curium US，Eli Lilly，Point Biopharma，Fusion，Astrazeneca，Endocyte，Progenics Pharmaceuticals，Inc.，AdvanCell Isotopes Pty Limited等，正在开发新的放射性配体治疗，未来几年可在放射性配体治疗市场上获得。。

Some of the key radioligand therapies include 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225^Ac-PSMA-617, I-131-1095, [212Pb]Pb-ADVC001, and others.

。

In March 2024, Novartis announced that it had acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. As per terms of the agreement, Novartis is expected to make an upfront payment of $1 billion, with further potential payments of up to $750 million upon the completion of pre-specified milestones..

2024年3月，诺华宣布收购了Mariana Oncology，这是一家专门开发用于癌症治疗的放射性配体疗法（RLT）的生物技术公司。根据协议条款，诺华预计将支付10亿美元的预付款，在完成预先规定的里程碑后，还可能支付高达7.5亿美元的款项。。

In March 2024, AstraZeneca announced that it will acquire Fusion Pharmaceuticals for USD 2 billion to accelerate the development of next-generation radioconjugates to treat cancer. The acquisition brings new expertise and pioneering R&D, manufacturing, and supply chain capabilities in actinium-based RCs to AstraZeneca.

2024年3月，阿斯利康宣布将斥资20亿美元收购Fusion Pharmaceuticals，以加速开发用于治疗癌症的下一代放射性结合物。此次收购为阿斯利康带来了基于锕的RCs的新专业知识和开创性的研发、制造和供应链能力。

In January 2024, the FDA approved Novartis's new automated radioligand therapy production plant for PLUVICTO—a radioligand therapy (RLT) for prostate cancer.

2024年1月，美国食品和药物管理局（FDA）批准诺华新的自动化放射性配体治疗生产厂用于治疗前列腺癌的放射性配体治疗（RLT）。

In January 2024, InHealth launched the United Kingdom's first relocatable radioligand therapy service.

2024年1月，InHealth推出了英国首个可重新定位的放射性配体治疗服务。

In October 2023, Lilly acquired Point Biopharma with USD 1.4 billion and deepened its oncology pipeline. In the deal, Lilly will gain ownership of Point's lead asset PNT2002, a radioligand therapy against targeting the prostate-specific membrane antigen (PSMA), being trialed for patients with metastatic castration-resistant prostate cancer who had progressed after hormonal treatment.

2023年10月，礼来以14亿美元收购了Point Biopharma，并深化了其肿瘤学渠道。在这笔交易中，礼来将获得Point领先资产PNT2002的所有权，这是一种针对前列腺特异性膜抗原（PSMA）的放射性配体疗法，正在针对激素治疗后进展的转移性去势抵抗性前列腺癌患者进行试验。

The candidate carries the beta-emitting radioisotope lutetium-177..

候选人携带发射β放射性同位素lutetium-177。。

Discover which therapies are expected to grab the radioligand therapies market share @ Radioligand Therapies Market Report

发现哪些疗法有望抢占放射性配体疗法市场份额@放射性配体疗法市场报告

Radioligand Therapies Market Dynamics

放射性配体疗法市场动态

The radioligand therapies market has witnessed significant dynamics driven by advancements in oncology and nuclear medicine. One of the key drivers of market growth is the increasing incidence of cancer worldwide. As cancer rates rise, there is a growing demand for effective therapies that can improve patient outcomes and quality of life.

放射配体疗法市场在肿瘤学和核医学的进步推动下取得了重大进展。市场增长的关键驱动因素之一是全球癌症发病率的增加。随着癌症发病率的上升，对能够改善患者预后和生活质量的有效疗法的需求越来越大。

Radioligand therapies, such as those targeting prostate-specific membrane antigen (PSMA) for prostate cancer or somatostatin receptors for neuroendocrine tumors, have shown promising results in clinical trials, fueling their adoption in clinical practice..

放射性配体疗法，例如针对前列腺癌的前列腺特异性膜抗原（PSMA）或针对神经内分泌肿瘤的生长抑素受体的疗法，在临床试验中显示出有希望的结果，推动了其在临床实践中的采用。。

Moreover, technological advancements in imaging and radiopharmaceutical production have bolstered the development and commercialization of radioligand therapies. The integration of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging has enhanced the diagnosis and staging of cancers, facilitating the selection of appropriate patients for radioligand therapy..

此外，成像和放射性药物生产的技术进步促进了放射性配体疗法的发展和商业化。正电子发射断层扫描（PET）和单光子发射计算机断层扫描（SPECT）成像的整合增强了癌症的诊断和分期，有助于选择合适的患者进行放射性配体治疗。。

Market dynamics also include regulatory approvals and reimbursement policies, which play a critical role in the adoption and accessibility of radioligand therapies. Regulatory agencies worldwide are increasingly recognizing the potential of these therapies, expediting their approval processes for various cancer types.

市场动态还包括监管批准和报销政策，这些政策在放射性配体疗法的采用和可及性方面起着至关重要的作用。世界各地的监管机构越来越认识到这些疗法的潜力，加快了各种癌症类型的批准程序。

Furthermore, efforts to streamline reimbursement pathways are essential in ensuring that patients can afford these innovative treatments..

此外，简化报销途径的努力对于确保患者能够负担得起这些创新治疗至关重要。。

Looking forward, collaborations between pharmaceutical companies, academic institutions, and healthcare providers are expected to drive further advancements in radioligand therapies. These partnerships facilitate research and development initiatives, clinical trials, and the establishment of treatment guidelines, ultimately expanding the therapeutic landscape for cancer patients globally.

展望未来，制药公司，学术机构和医疗保健提供者之间的合作有望推动放射性配体疗法的进一步进步。这些伙伴关系促进了研究和开发计划，临床试验和治疗指南的建立，最终扩大了全球癌症患者的治疗前景。

As the field continues to evolve, ongoing research into novel targets and isotopes promises to unlock new opportunities for personalized and effective cancer treatment strategies..

随着该领域的不断发展，对新靶点和同位素的持续研究有望为个性化和有效的癌症治疗策略开辟新的机会。。

Radioligand Therapies Treatment Market

放射性配体疗法治疗市场

Radioligand therapies are a burgeoning treatment modality for diverse cancers. They demonstrate efficacy in enhancing progression-free survival and quality of life for neuroendocrine tumors, and in improving overall survival for metastatic castration-resistant prostate cancer, prompting their inclusion in cancer care guidelines.

放射性配体疗法是多种癌症的新兴治疗方式。他们证明了在提高神经内分泌肿瘤的无进展生存期和生活质量方面的功效，以及在提高转移性去势抵抗性前列腺癌的总体生存率方面的功效，促使他们将其纳入癌症护理指南。

Moreover, RLT holds promise for treating aggressive or rare cancers, especially metastatic cases lacking effective therapies..

此外，RLT有望治疗侵袭性或罕见癌症，尤其是缺乏有效治疗的转移性病例。。

Several RLTs, including LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN, are FDA-approved. LUTATHERA represents a significant breakthrough as the inaugural treatment sanctioned specifically for pediatric patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval signals a new prospect for young individuals grappling with this uncommon form of cancer.

包括LUTATHERA，PLUVICTO，XOFIGO和ZEVALIN在内的几种RLT已获得FDA批准。。这一批准标志着与这种罕见癌症作斗争的年轻人有了新的前景。

Moreover, LUTATHERA has also been endorsed in Europe for adults with unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs, and in Japan for SSTR-positive NETs..

此外，LUTATHERA在欧洲也被认可用于无法切除或转移，进行性，分化良好（G1和G2），SSTR阳性GEP NETs的成年人，在日本也被认可用于SSTR阳性NETs。。

LUTATHERA is a radioactive medication designed to target somatostatin receptors found on certain tumor cells. By binding to these receptors and entering the cells, the drug delivers radiation that can effectively damage the tumor cells.

LUTATHERA是一种放射性药物，旨在靶向某些肿瘤细胞上发现的生长抑素受体。通过与这些受体结合并进入细胞，该药物可以提供有效损伤肿瘤细胞的辐射。

PLUVICTO represents the first FDA-approved targeted radioligand therapy for eligible patients suffering from mCRPC, integrating a targeting molecule (ligand) with a therapeutic radioisotope. The active component of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177, which is coupled with a moiety that binds to PSMA, a transmembrane protein expressed in prostate cancer, including mCRPC.

PLUVICTO代表了FDA批准的第一种针对mCRPC合格患者的靶向放射性配体疗法，将靶向分子（配体）与治疗性放射性同位素整合在一起。Lu 177 vipivotide tetraxetan的活性成分是放射性核素Lu-177，它与结合PSMA的部分结合，PSMA是前列腺癌（包括mCRPC）中表达的跨膜蛋白。

Once lutetium Lu 177 vipivotide tetraxetan attaches to PSMA-expressing cells, the beta-minus emissions from lutetium-177 deliver radiation to both PSMA-expressing cells and neighboring cells, inducing DNA damage that may result in cell death. PLUVICTO achieved sales exceeding USD 950 million..

一旦lutetium Lu 177 vipivotide tetraxetan附着到表达PSMA的细胞上，lutetium-177的β-负发射将辐射传递到表达PSMA的细胞和邻近细胞，诱导DNA损伤，可能导致细胞死亡。PLUVICTO销售额超过9.5亿美元。。

NOVARTIS currently offers two RLTs globally, with multiple others in development and over 15 clinical trials underway or planned. The sector has seen acquisitions, such as AstraZeneca's acquisition of Fusion Pharmaceutical, advancing its RLT FPI-2265 into phase II/III clinical trials.

诺华目前在全球范围内提供两个RLT，其他多个正在开发中，正在进行或计划进行15多项临床试验。该行业已经进行了收购，例如阿斯利康收购Fusion Pharmaceutical，将其RLT FPI-2265推进II/III期临床试验。

Learn more about the FDA-approved radioligand therapies @ Radioligand Therapies Drugs

了解有关FDA批准的放射性配体疗法@放射性配体疗法药物的更多信息

Key Emerging Radioligand Therapies and Companies

主要新兴放射性配体疗法和公司

Several key players, including AstraZeneca/Fusion (FPI-2265), Eli Lilly (Lu-PNT2002), Curium (177Lu-PSMA-I&T), and others, are involved in developing drugs for radioligand therapies for various indications such as prostate cancer, pancreatic cancer, and others.

包括阿斯利康/融合（FPI-2265），礼来（Lu-PNT2002），Curium（177Lu-PSMA-I＆T）等在内的几个关键参与者参与了针对各种适应症的放射性配体治疗药物的开发，如前列腺癌，胰腺癌等。

177Lu-PSMA-I&T targets prostate-specific membrane antigen, found in over 85% of prostate cancer cells. Due to its high specificity for this antigen, the radioisotope selectively targets these cancer cells. Upon binding to the cancer cell, the radioisotope is taken up internally, where its radioactive properties disrupt the cancer cell's DNA strands, effectively killing it..

177Lu-PSMA-I＆T靶向前列腺特异性膜抗原，在超过85%的前列腺癌细胞中发现。由于其对该抗原的高度特异性，放射性同位素选择性地靶向这些癌细胞。在与癌细胞结合后，放射性同位素被内部吸收，其放射性特性破坏了癌细胞的DNA链，有效地杀死了癌细胞。。

Lantheus Holdings holds exclusive global commercialization rights (excluding specific Asian territories) for 177Lu-PNT2002, a potential radioligand therapy utilizing PSMA-targeted ligand PSMA-I&T paired with the beta-emitting radioisotope no-carrier-added lutetium-177. The therapy, developed by POINT, gained Fast Track designation from the FDA in April 2023 for treating mCRPC..

Lantheus Holdings拥有177Lu-PNT2002的独家全球商业化权利（不包括特定的亚洲地区），这是一种潜在的放射性配体疗法，利用PSMA靶向配体PSMA-I＆T与β发射放射性同位素no载体添加的lutetium-177配对。该疗法由POINT开发，于2023年4月获得FDA的快速通道指定，用于治疗mCRPC。。

Other radioligand therapies in the pipeline include

正在进行的其他放射性配体疗法包括

FPI-2265: AstraZeneca/Fusion

FPI-2265：阿斯利康/融合

225^Ac-PSMA-617: Endocyte

225 ^ Ac-PSMA-617：内吞细胞

I-131-1095: Progenics Pharmaceuticals, Inc.

I-131-1095：Progenics Pharmaceuticals，Inc。

[212Pb]Pb-ADVC001: AdvanCell Isotopes Pty Limited

[212Pb]Pb-ADVC001：AdvanCell同位素私人有限公司

The anticipated launch of these emerging therapies are poised to transform the radioligand therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Radioligand Therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

预计这些新兴疗法的推出将在未来几年改变放射性配体疗法的市场格局。随着这些尖端疗法的不断成熟并获得监管部门的批准，预计它们将重塑放射性配体疗法的市场格局，为医疗创新和经济增长提供新的护理标准和解锁机会。。

To know more about radioligand therapies clinical trials, visit @ Radioligand Therapies Treatment Drugs

Radioligand Therapies Overview

放射性配体疗法概述

Radioligand therapies (RLT) represent a specialized form of targeted nuclear medicine designed to detect and treat diseases like cancer. These therapies deliver radiation specifically to cancer cells that exhibit particular targets. RLT marks a significant stride in precision oncology, providing a focused approach to combating cancer..

放射性配体疗法（RLT）代表了靶向核医学的一种特殊形式，旨在检测和治疗癌症等疾病。这些疗法专门向表现出特定靶标的癌细胞提供辐射。RLT标志着精准肿瘤学的重大进步，为抗击癌症提供了一种专注的方法。。

RLT involves two main components: a radioisotope and a cell-targeting compound (ligand), chemically linked together. The radioisotope emits radiation that targets and destroys specific cancer cells, while the ligand attaches to cells expressing these specific targets, guiding the radioisotope to its intended destination..

RLT涉及两个主要成分：放射性同位素和化学连接在一起的细胞靶向化合物（配体）。放射性同位素发出的辐射靶向并破坏特定的癌细胞，而配体附着在表达这些特定靶标的细胞上，将放射性同位素引导至其预期目的地。。

Therapeutic radioisotopes are typically produced in dedicated nuclear reactors or generators, and then transported to production facilities where they are combined with the cell-targeting compound. The final product is packaged in vials, undergoes rigorous quality testing, is secured in special lead-shielded containers, and finally shipped directly to hospitals or clinics as a ready-to-administer therapy..

治疗性放射性同位素通常在专用的核反应堆或发电机中生产，然后运输到生产设施，在那里它们与细胞靶向化合物结合。最终产品用小瓶包装，经过严格的质量测试，固定在特殊的铅屏蔽容器中，最后直接运送到医院或诊所，作为随时可用的治疗方法。。

Radioligand Therapies Report Metrics

放射性配体疗法报告指标

Details

详细信息

Study Period

研究期间

2020–2034

2020–2034

Radioligand Therapies Report Coverage

放射性配体疗法报告覆盖率

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]

Key Radioligand Therapies Companies

主要放射性配体治疗公司

Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca, Endocyte, Progenics Pharmaceuticals, Inc., AdvanCell Isotopes Pty Limited, and others

库里姆美国，礼来，Point Biopharma，Fusion，阿斯利康，Endocyte，Progenics Pharmaceuticals，Inc.，AdvanCell Isotopes Pty Limited等

Key Radioligand Therapies

关键放射性配体疗法

177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225^Ac-PSMA-617, I-131-1095, [212Pb]Pb-ADVC001, and others

177Lu-PSMA-I＆T，Lu-PNT2002，FPI-2265225 ^ Ac-PSMA-617，I-131-1095，[212Pb]Pb-ADVC001等

Scope of the Radioligand Therapies Market Report

Radioligand Therapies Therapeutic Assessment: Radioligand Therapies current marketed and emerging therapies

放射性配体疗法治疗评估：放射性配体疗法当前上市和新兴疗法

Radioligand Therapies Market Dynamics: Attribute Analysis of Emerging Radioligand Therapies Drugs

放射性配体疗法市场动态：新兴放射性配体疗法药物的属性分析

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争情报分析：SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Radioligand Therapies Market Access and Reimbursement

未满足的需求、KOL的观点、分析师的观点、放射性配体疗法的市场准入和报销

Discover more about radioligand therapies in development @ Radioligand Therapies Clinical Trials

了解更多关于放射性配体疗法的开发@放射性配体疗法临床试验

Table of Contents

目录

1.

1.

Radioligand Therapies Market Key Insights

放射性配体疗法市场关键见解

2.

2.

Radioligand Therapies Market Report Introduction

放射性配体疗法市场报告简介

3.

3.

Radioligand Therapies Market Overview at a Glance

放射性配体疗法市场概览

4.

4.

Radioligand Therapies Market Executive Summary

放射性配体疗法市场执行摘要

5.

5.

Disease Background and Overview

疾病背景和概述

6.

6.

Radioligand Therapies Treatment and Management

7.

7.

Radioligand Therapies Epidemiology and Patient Population

放射性配体疗法流行病学和患者人群

8.

8.

Patient Journey

患者旅程

9.

9.

Radioligand Therapies Marketed Drugs

放射性配体疗法上市药物

10.

10.

Radioligand Therapies Emerging Drugs

放射性配体疗法新兴药物

11.

11.

Seven Major Radioligand Therapies Market Analysis

七大放射性配体疗法市场分析

12.

12.

Radioligand Therapies Market Outlook

放射性配体疗法市场前景

13.

13.

Potential of Current and Emerging Therapies

当前和新兴疗法的潜力

14.

14.

KOL Views

KOL Views

15.

15.

Unmet Needs

未满足的需求

16.

16.

SWOT Analysis

17.

17.

Appendix

附录

18.

18.

DelveInsight Capabilities

DelveInsight功能

19.

19.

Disclaimer

免责声明

20.

20.

About DelveInsight

关于DelveInsight

Related Reports

相关报告

Nuclear Medicine Market

核医学市场

Nuclear Medicine Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key nuclear medicine companies, including Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, Eczacıbaşı-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, among others..

《2030年核医学市场洞察、竞争格局和市场预测报告》深入了解了市场趋势、市场驱动因素、市场障碍以及包括Lantheus在内的主要核医学公司。，红衣主教健康状况。，GE Healthcare、Curium Pharma、Nihon Medi Physics Co.，Ltd.、Novartis（Advanced Accelerator Applications）、Cambridge Isotopes Laboratories，Inc、Sotera Health LLC、Bracco Imaging SpA、Jubilant Pharma Limited、Necsa、IBA Radiopharma Solutions、Bayer AG、Norgine、Eczacıbaşı-Monrol、NorthStar Medical Radiosotopes，LLC、Eckert&Ziegler、。，Telix Pharmaceuticals Limited、ITM同位素技术慕尼黑SE、Mallinckrodt PLC等。。

Gastroenteropancreatic Neuroendocrine Tumors Market

胃肠胰神经内分泌肿瘤市场

Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key GEP-NETs companies including Eli Lilly and Company, Phanes Therapeutics, Novatek Pharmaceuticals, Camurus AB, Advanced Accelerator Applications, RayzeBio, Inc., Aadi Bioscience, Inc., PharmaMar, among others..

胃肠胰神经内分泌肿瘤市场洞察、流行病学和市场预测-2032年报告深入了解了该疾病、历史和预测流行病学、个体疗法的市场份额以及关键的GEP NETs公司，包括礼来公司、Phanes Therapeutics、Novatek Pharmaceuticals、Camurus AB、Advanced Accelerator Applications、RayzeBio，Inc.、Aadi Bioscience，Inc.、PharmaMar等。。

Neuroendocrine Tumors Market

神经内分泌肿瘤市场

Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key neuroendocrine tumors companies including Radiomedix, Inc, Orano Med LLC, Molecular Targeting Technologies, Inc., Viewpoint Molecular Targeting, Exelixis, Eli Lilly and Company, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Camurus AB, Hutchmed, Merck Sharp & Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, RayzeBio, Inc., Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, among others..

神经内分泌肿瘤市场见解、流行病学和市场预测-2032年报告深入了解了该疾病、历史和预测流行病学、个体疗法的市场份额以及关键的神经内分泌肿瘤公司，包括Radiomedix，Inc，Orano Med LLC，Molecular Targeting Technologies，Inc.，Viewpoint Molecular Targeting，Exelixis，Eli Lilly and Company，Teclison Ltd.，Novatek Phanes Therapeutics，Camurus AB，Hutchmed，Merck Sharp＆Dohme LLC，BioXcel Therapeutics Inc.，Boehringer Ingelheim，RayzeBio，Inc.，Vyriad，Inc.，Hoffmann-La Roche，Monte Rosa Therapeutics，Inc，Amgen，ORIC Pharmaceuticals等。。

Neuroendocrine Tumors Pipeline

神经内分泌肿瘤管道

Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroendocrine tumors companies, including Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, among others..

神经内分泌肿瘤管道洞察-2024年报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键神经内分泌肿瘤公司的全面见解，包括江苏恒瑞医药，Medimune，Genentech，Merck＆Co，辉瑞，武田肿瘤学，和记医药，Provectus Biopharmaceuticals，NanoValent Pharmaceuticals，Camurus，ITM Solucin，Pfizer，Radiomedix，Inc.，Orano Med LLC，Clarity Pharmaceuticals，TaiRx，Peloton Therapeutics，RayzeBio，Ascentage Pharma，Debiopharm，勃林格殷格翰，罗氏，Ipsen，Medelis Inc.，Exelixis，EpicentRx，Inc.，Tarveda Therapeutics，Teclison Ltd.，Novatek Pharmaceuticals，Phanes Therapeutics，Fujifilm Pharmaceuticals，Jazz Pharmaceuticals，23andMe，Inc.，Celgene，Crinetics Pharmaceuticals Inc.，POINT Biopharma等。。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

。它通过提供全面的端到端解决方案来提高制药公司的绩效，从而为制药公司提供支持。通过我们基于订阅的平台PharmDelve，轻松访问所有医疗保健和制药市场研究报告。。

Contact UsShruti Thakurinfo@delveinsight.com +14699457679

联系UsshrutiThakurinfo@delveinsight.com+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

标志https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research，LLP